Related Experiment Videos
Adverse reactions to trimethoprim-sulfamethoxazole, with particular reference to long-term therapy
Abstract:
Since trimethoprim-sulfamethoxazole (TMP-SMX) was first marked occasional reviews have surveyed the pattern of adverse reactions. Skin rashes characteristic of sulfonamide sensitivity have predominated, with relatively few of a serious exfoliative nature. Hematologic adverse reactions recorded follow the pattern known to occur with sulfonamides, with a few cases related to the action of trimethoprim on human folate metabolism. Such an effect is more likely to occur when the patient's folate status is already jeopardized; it is rare in relation to the widespread use of the drug combination. Long-term administration does not per se seem to represent an additional hazard provided the dose is the correct one and the hematologic monitoring of the patient is performed regularly. The suggestion that TMP-SMX has a toxic effect on the kidney has not been substantiated. An estimated 250 million "standard treatment courses" have been given in the first 6 years of marketing and, overall, the picture of adverse reactions corresponds with that expected from a sulfonamide of relatively low toxicity.
Insights
Trimethoprim-sulfamethoxazole (TMP-SMX) exhibits a low toxicity profile, with skin rashes being the most common adverse reaction. Hematologic effects are rare and typically occur in patients with compromised folate status.
Area of Science:
- Pharmacology
- Clinical Medicine
- Drug Safety
Background:
- Trimethoprim-sulfamethoxazole (TMP-SMX) is a widely used antibiotic combination.
- Adverse reactions to TMP-SMX have been periodically reviewed since its market introduction.
- Understanding the safety profile is crucial for appropriate clinical use.
Purpose of the Study:
- To review and characterize the pattern of adverse reactions associated with trimethoprim-sulfamethoxazole (TMP-SMX).
- To assess the safety of long-term TMP-SMX administration.
- To evaluate reported renal toxicity concerns.
Main Methods:
- Review of reported adverse reactions from clinical use.
- Analysis of adverse event patterns, including skin reactions and hematologic effects.
- Evaluation of data regarding kidney function and long-term safety.
Main Results:
- Skin rashes, indicative of sulfonamide sensitivity, are the predominant adverse reactions, with few serious exfoliative cases.
- Hematologic adverse reactions are uncommon and align with known sulfonamide effects, occasionally linked to trimethoprim's impact on folate metabolism.
- Long-term use is generally safe with correct dosing and regular hematologic monitoring; renal toxicity is unsubstantiated.
Conclusions:
- Trimethoprim-sulfamethoxazole demonstrates a relatively low toxicity profile, consistent with its classification as a sulfonamide.
- The overall pattern of adverse reactions is predictable and manageable.
- Extensive use supports its favorable safety profile when administered appropriately.